Provided by Tiger Fintech (Singapore) Pte. Ltd.

HANSOH PHARMA

24.350
+0.2501.04%
Volume:843.04K
Turnover:20.32M
Market Cap:144.81B
PE:30.90
High:24.350
Open:23.900
Low:23.700
Close:24.100
Loading ...

BRIEF-Hansoh Pharmaceutical Recommends Final Dividend Of HK$13.53 Cents Per Share

Reuters
·
21 Mar

Hansoh Pharmaceutical - Board Recommends a Final Dividend of HK$13.53 Cents per Share

THOMSON REUTERS
·
21 Mar

Hansoh Pharmaceutical Group Company FY Net Income RMB 4,372 Million

THOMSON REUTERS
·
21 Mar

Hansoh Pharmaceutical Gets Registration Go-Ahead for Third Indication of Cancer Drug

MT Newswires Live
·
11 Mar

BRIEF-Hansoh Pharmaceutical Says NMPA Granted Drug Registration Approval Of Third Indication Of Ameile

Reuters
·
10 Mar

Hansoh Pharmaceutical - Drug Registration Approval of Third Indication of Ameile (Aumolertinib Mesilate Tablets) Granted by Nmpa

THOMSON REUTERS
·
10 Mar

Greater China Stocks Slip; Hong Kong Sees Largest Decline

Dow Jones
·
10 Mar

Chinese Regulator Accepts Second BLA for Anti-Inflammatory Drug Licensed by Hansoh Pharmaceutical

MT Newswires Live
·
05 Mar

BRIEF-Hansoh Pharmaceutical Says Second Biologics License Application Of Xinyue Accepted By NMPA

Reuters
·
04 Mar

Hansoh Pharmaceutical - Second Biologics License Application of Xinyue Accepted by Nmpa

THOMSON REUTERS
·
04 Mar

Earnings are growing at Hansoh Pharmaceutical Group (HKG:3692) but shareholders still don't like its prospects

Simply Wall St.
·
03 Mar

Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$18.36 From HK$17.95, Keeps at Neutral

MT Newswires Live
·
26 Feb

Hansoh Pharmaceutical Group's Anti-Hives Capsule Obtains Chinese Regulator's Approval for Clinical Trials

MT Newswires Live
·
25 Feb

Chinese Regulator Designates Hansoh Pharmaceutical Group's Injection as Breakthrough-Therapy Drug for Bone Cancer

MT Newswires Live
·
25 Feb

BRIEF-Hansoh Pharmaceutical Says NMPA Granted Approval For HS-20093

Reuters
·
25 Feb

BRIEF-Hansoh Pharmaceutical Receives Clinical Trial Approval For Hs-10561 Capsules Issued By NMPA

Reuters
·
25 Feb

Hansoh Pharmaceutical - Nmpa Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate Hs-20093

THOMSON REUTERS
·
25 Feb

Hansoh Pharmaceutical - Clinical Trial Approval for Hs-10561 Capsules Issued by Nmpa

THOMSON REUTERS
·
25 Feb

Hansoh Pharmaceutical Says IgG4-Related Disease Drug Gets Priority Review from China Regulator

MT Newswires Live
·
10 Feb

Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?

Simply Wall St.
·
10 Feb